Stoke Therapeutics Inc STOK:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$18.10NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.04(0.22%)
Bid (Size)$18.20 (3)
Ask (Size)$18.21 (12)
Day Low / High$17.71 - 18.67
Volume191.4 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

Timeframe
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $18.10
Change: -0.04 (0.22%)
Volume: 191.4 K
4:00PM ET 1/21/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Chinook Therapeutics Inc ( NASDAQ )

Price: $12.72
Change: -0.36 (2.75%)
Volume: 258.5 K
4:00PM ET 1/21/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Rubius Therapeutics Inc ( NASDAQ )

Price: $7.30
Change: -0.40 (5.19%)
Volume: 681.9 K
4:00PM ET 1/21/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Ocugen Inc ( NASDAQ )

Price: $3.28
Change: -0.28 (7.87%)
Volume: 16.6 M
4:00PM ET 1/21/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

MeiraGTx Holdings PLC ( NASDAQ )

Price: $15.44
Change: -0.32 (2.03%)
Volume: 199.3 K
4:00PM ET 1/21/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

Acadia, Stoke to Develop RNA-Based Treatments for Genetic Neurological Disorders
10:52AM ET 1/10/2022 MT Newswires

Acadia Pharmaceuticals (ACAD) and Stoke Pharmaceuticals (STOK) said Monday they have formed a partnership to discover, develop and commercialize novel...

Stoke Therapeutics Shares Interim Data on STK-001 to Treat Dravet Syndrome
1:55PM ET 12/03/2021 MT Newswires

Stoke Therapeutics (STOK) said Friday that a phase 1/2a study of its STK-001 candidate to treat Dravet syndrome showed that 70.6% of patients saw a...

BofA Securities Starts Stoke Therapeutics at Buy With $43 Price Target
6:35AM ET 12/03/2021 MT Newswires

Stoke Therapeutics (STOK) has an average rating of outperform and price targets ranging from $34 to $83, according to analysts polled by Capital IQ. (MT...

Stoke Therapeutics Shares Rise Following JPMorgan Upgrade
1:54PM ET 11/22/2021 MT Newswires

Stoke Therapeutics (STOK) was up nearly 14% after JPMorgan upgraded the company to overweight from neutral. The investment firm's price target on the...

View all Commentary and Analysis

Stoke Therapeutics (STOK) Investor Presentation -Slideshow
2:11AM ET 12/01/2021 Seeking Alpha

Sizing Up Stoke Therapeutics
7:16AM ET 3/07/2021 Seeking Alpha

Company Profile

Business DescriptionStoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA. View company web site for more details
Address45 Wiggins Avenue
Bedford, Massachusetts 01730
Phone+1.781.430.8200
Number of EmployeesN/A
Chief Executive Officer & DirectorEdward M. Kaye
Chief Operating & Business OfficerHuw M. Nash
Chief Financial OfficerStephen J. Tulipano
Chief Medical OfficerBarry S. Ticho

Company Highlights

Price Open$17.81
Previous Close$18.14
52 Week Range$17.71 - 69.52
Market Capitalization$665.9 M
Shares Outstanding36.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.09
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-28.89%

Analyst Ratings as of 12/03/2021

Buy
10
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset